News

Frontiers1d
Community Series in Unveiling the Next Generation of Cancer Immunity & Immunotherapy in Lung Cancer: Volume II
The field of Cancer Immunity & Immunotherapy is entering an exciting new phase. While Volume I (see here) of this Research Topic highlighted broad ...
Stories by SWNS on MSN8d
Grandad beats stage four cancer with breakthrough immunotherapy
A grandad with advanced lung cancer which often leaves patients dead within four months has become free of the disease after ...
News-Medical.Net on MSN4d
SWOG S2302 Pragmatica-Lung study demonstrates value of streamlined clinical trials in real world settings
The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...
EurekAlert!5d
S2302 Pragmatica-Lung reports out as model for faster, leaner, more representative trials
The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...
Pharmabiz3d
US FDA accepts Roche’s sBLA and grants priority review status for Tecentriq to treat NSCLC
US FDA accepts Roche’s sBLA and grants priority review status for Tecentriq to treat NSCLC: Basel Wednesday, August 4, 2021, 12:00 Hrs [IST] Roche announced that the US Food and ...
Applied Clinical Trials Online4d
Tecentriq and Zepzelca Combo Demonstrates Significant Survival Benefit in Phase III Study for Extensive-Stage Small Cell Lung Cancer
In the Phase III IMforte trial, Tecentriq (atezolizumab) and Zepzelca (lurbinectedin) reduced the risk of disease progression ...
'I had stage four cancer but I'm now disease free after rare treatment'
Jeff Cook, 76, was diagnosed with stage four cancer in 2019 and was told that he needed radiotherapy to target the tumour ...
MedPage Today on MSN4d
Pre-Op Osimertinib in Lung Cancer Leads to More Major Pathologic Responses
CHICAGO -- Neoadjuvant osimertinib (Tagrisso) with or without chemotherapy significantly increased major pathologic response ...
Taiwan News5d
Roche’s Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III IMforte study of Tecentriq® (atezolizumab) in combination with lurbinectedin (Zepzelca®) as a first-line ...